The RISE Above Depression trial explores the impact of remote and in-person treatment settings on participants' ability to attend study sessions and adhere to treatment and study protocols. Participants will be recruited based on depression symptomology and provided with Moodivate, an mHealth depression intervention, while meeting with study staff for a total of 6 sessions in a 4-month period. The trial's experimental core is the 2-stage randomization process. Eligible participants are first randomized to attend either a remote or in-person intake session and then randomized again at intake to determine whether their remaining 5 sessions will take place remotely or in-person. The resultant 4-cell design allows for a balanced and rigorous assessment of the differences between participant accrual, retention, treatment adherence, and biospecimen collection in remote versus in-person settings.